Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 4
2005 4
2006 1
2007 5
2008 7
2009 4
2010 6
2011 5
2012 2
2013 5
2014 7
2015 8
2016 4
2017 5
2018 5
2019 1
2020 5
2021 5
2022 5
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Rummel MJ, et al. Among authors: hinke a. Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Lancet. 2013. PMID: 23433739 Clinical Trial.
SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of 'biomarker-defined early multiple myeloma'-a systematic review with meta-analysis.
Ludwig H, Kainz S, Schreder M, Zojer N, Hinke A. Ludwig H, et al. Among authors: hinke a. EClinicalMedicine. 2023 Mar 20;58:101910. doi: 10.1016/j.eclinm.2023.101910. eCollection 2023 Apr. EClinicalMedicine. 2023. PMID: 36969337 Free PMC article.
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial.
Stein A, Paschold L, Tintelnot J, Goekkurt E, Henkes SS, Simnica D, Schultheiss C, Willscher E, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich T, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran SE, Reinacher-Schick A, Pink D, Sinn M, Lindig U, Hiegl W, Hinke A, Hegewisch-Becker S, Binder M. Stein A, et al. Among authors: hinke a. JAMA Oncol. 2022 Aug 1;8(8):1150-1158. doi: 10.1001/jamaoncol.2022.2228. JAMA Oncol. 2022. PMID: 35737383 Free PMC article. Clinical Trial.
Response.
Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz UA, Runnebaum IB, Hinke A, Kreienberg R, Untch M; AGO Breast Study Group. Moebus V, et al. Among authors: hinke a. J Natl Cancer Inst. 2014 Mar;106(3):djt452. doi: 10.1093/jnci/djt452. Epub 2014 Feb 28. J Natl Cancer Inst. 2014. PMID: 24586093 No abstract available.
IMWG consensus on maintenance therapy in multiple myeloma.
Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M; International Myeloma Working Group. Ludwig H, et al. Among authors: hinke a. Blood. 2012 Mar 29;119(13):3003-15. doi: 10.1182/blood-2011-11-374249. Epub 2012 Jan 23. Blood. 2012. PMID: 22271445 Free PMC article. Review.
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.
Lorenzen S, Thuss-Patience P, Pauligk C, Gökkurt E, Ettrich T, Lordick F, Stahl M, Reichardt P, Sökler M, Pink D, Probst S, Hinke A, Goetze TO, Al-Batran SE. Lorenzen S, et al. Among authors: hinke a. Eur J Cancer. 2022 Apr;165:48-57. doi: 10.1016/j.ejca.2022.01.015. Epub 2022 Feb 21. Eur J Cancer. 2022. PMID: 35202974 Clinical Trial.
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis.
Adams R, Goey K, Chibaudel B, Koopman M, Punt C, Arnold D, Hinke A, Hegewisch-Becker S, de Gramont A, Labianca R, Diaz Rubio E, Magne Tveit K, Wasan H, Kaplan R, Brown L, Maughan T, Fisher D. Adams R, et al. Among authors: hinke a. Cancer Treat Rev. 2021 Sep;99:102226. doi: 10.1016/j.ctrv.2021.102226. Epub 2021 May 19. Cancer Treat Rev. 2021. PMID: 34130171 Review.
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass).
Grünwald V, Ivanyi P, Zschäbitz S, Wirth M, Staib P, Schostak M, Dargatz P, Müller L, Metz M, Bergmann L, Steiner T, Welslau M, Lorch A, Rafiyan R, Hellmis E, Darr C, Schütt P, Meiler J, Kretz T, Loidl W, Flörcken A, Mänz M, Hinke A, Hartmann A, Grüllich C. Grünwald V, et al. Among authors: hinke a. Eur Urol. 2023 Dec;84(6):571-578. doi: 10.1016/j.eururo.2023.09.004. Epub 2023 Sep 26. Eur Urol. 2023. PMID: 37758574 Clinical Trial.
83 results